Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.

BACKGROUND-Several cases of unexpected death have been reported with sildenafil in patients predisposed to ischemic cardiac events. Although acute episodes of ischemia could account for some of these deaths, we hypothesized that sildenafil may have unsuspected electrophysiological effects predisposing some patients to proarrhythmia. METHODS AND RESULTS-Studies were undertaken in 10 isolated guinea pig hearts that demonstrated prolongation of cardiac repolarization in a reverse use-dependent manner by sildenafil 30 mcmol/L. Action potential duration increased 15% from baseline 117+/-3 to 134+/-2 ms with sildenafil during pacing at 250 ms cycle length, whereas a 6% increase from 99+/-2 to 105+/-2 ms was seen with pacing at 150 ms cycle length. Experiments in human ether-a-go-go-related gene (HERG)-transfected HEK293 cells (n=30) demonstrated concentration-dependent block of the rapid component (I(Kr)) of the delayed rectifier potassium current: activating current was 50% decreased at 100 mcmol/L. This effect was confirmed using HERG-transfected Chinese hamster ovary (CHO) cells, which exhibit no endogenous I(K)-like current. CONCLUSIONS-Sildenafil possesses direct cardiac electrophysiological effects similar to class III antiarrhythmic drugs. These effects are observed at concentrations that may be found in conditions of impaired drug elimination such as renal or hepatic insufficiency, during coadministration of another CYP3A substrate/inhibitor, or after drug overdose and offer a new potential explanation for sudden death during sildenafil treatment.

[1]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[2]  B. Drolet,et al.  Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. , 1998, Circulation.

[3]  S. Kaul,et al.  Writing Group Members , 2022 .

[4]  Jay S. Cohen Should Patients be Given an Initial Low Test Dose of Sildenafil? , 2000, Drug safety.

[5]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[6]  R. Clark,et al.  Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support. , 1996, Critical care medicine.

[7]  I. Osterloh,et al.  Overall cardiovascular profile of sildenafil citrate. , 1999, The American journal of cardiology.

[8]  G. Muirhead,et al.  Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. , 2000, British journal of clinical pharmacology.

[9]  P. Daleau,et al.  Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. , 1995, Circulation.

[10]  S. Priori Exploring the Hidden Danger of Noncardiac Drugs , 1998, Journal of cardiovascular electrophysiology.

[11]  F. Montorsi Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction—by Morales et al , 1998, International Journal of Impotence Research.

[12]  P. Wright,et al.  Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  M. Goldenberg,et al.  Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. , 1998, Clinical therapeutics.

[14]  G. Kerchner,et al.  Endogenous voltage‐gated potassium channels in human embryonic kidney (HEK293) cells , 1998, Journal of neuroscience research.

[15]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.

[16]  P. Daleau,et al.  Modulation of HERG potassium channel properties by external pH , 1999, Pflügers Archiv.

[17]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[18]  Conti Cr VIAGRA, THE LATEST CARDIO-VASCULAR DRUG , 1998 .

[19]  M. Nassar Viagra®, the latest cardio‐vascular drug , 1999, Clinical cardiology.

[20]  I. Goldstein,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.

[21]  J. Lynch,et al.  Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. , 1995, Circulation research.

[22]  R. A. Murphy,et al.  Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. , 1998, The Journal of urology.